Extraosseous accumulation of (99m)Tc-HMDP to radiation nephropathy, mimicking recurrent neuroblastoma

Ann Nucl Med. 2005 Feb;19(1):35-40. doi: 10.1007/BF02986333.

Abstract

Objective: The aim of this study is to clarify the period of extraosseous accumulation of (99m)Tc-hydroxymethylenediphosphonate (HMDP) to radiation nephropathy mimicking recurrent or remnant neuroblastoma in the pararenal region.

Methods: We reviewed five neuroblastoma and one ganglioneuroblastoma patients (2 boys and 4 girls aged 1-9 years) who underwent (99m)Tc-HMDP bone scintigraphies periodically before and after radiation therapy.

Results: Increased renal uptake coincident with the radiation port appeared in 5 of 6 patients from 0 to 3 months (mean 1.7 months), and persisted up to 7 months after the completion of radiotherapy. Renal uptake of (99m)Tc-HMDP was gradually decreased, and eventually became accumulation defects in 5 of 6 patients from 6 to 17 months (mean 8.9 months) after radiotherapy.

Conclusion: When extraosseous accumulation is found after radiation therapy in neuroblastoma patients, radiation nephropathy would be a candidate in the differential diagnosis besides recurrent or remnant tumor.

Publication types

  • Case Reports

MeSH terms

  • Bone Neoplasms / diagnostic imaging
  • Bone Neoplasms / metabolism
  • Bone Neoplasms / secondary
  • Child
  • Child, Preschool
  • Diagnosis, Differential
  • Diagnostic Errors / prevention & control
  • Female
  • Humans
  • Infant
  • Kidney / diagnostic imaging
  • Kidney / injuries
  • Kidney / metabolism
  • Kidney / radiation effects
  • Kidney Diseases / diagnostic imaging*
  • Kidney Diseases / metabolism*
  • Male
  • Neoplasm Recurrence, Local / diagnostic imaging
  • Neoplasm Recurrence, Local / metabolism
  • Neuroblastoma / diagnostic imaging*
  • Neuroblastoma / metabolism*
  • Neuroblastoma / secondary
  • Radiation Injuries / diagnostic imaging*
  • Radiation Injuries / etiology
  • Radiation Injuries / metabolism*
  • Radionuclide Imaging
  • Radiopharmaceuticals / pharmacokinetics
  • Radiotherapy / adverse effects
  • Technetium Tc 99m Medronate / analogs & derivatives*
  • Technetium Tc 99m Medronate / pharmacokinetics*

Substances

  • Radiopharmaceuticals
  • technetium Tc 99m hydroxymethylene diphosphonate
  • Technetium Tc 99m Medronate